Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update
Ultragenyx Pharmaceutical (NASDAQ: RARE), a biopharmaceutical company specializing in novel products for rare and ultrarare genetic diseases, has announced a conference call scheduled for February 13, 2025, at 5:00 p.m. ET. The call will discuss the company's financial results and provide a corporate update for both the fourth quarter and full year ending December 31, 2024. Investors and interested parties can access the live webcast and replay through the company's investor relations website. The replay will remain available for three months following the call.
Ultragenyx Pharmaceutical (NASDAQ: RARE), un'azienda biopharmaceuticals specializzata in prodotti innovativi per malattie genetiche rare e ultrarare, ha annunciato una conference call programmata per il 13 febbraio 2025, alle 17:00 ET. Durante la chiamata si discuteranno i risultati finanziari dell'azienda e ci sarà un aggiornamento aziendale per il quarto trimestre e per l'intero anno che si chiude il 31 dicembre 2024. Gli investitori e le parti interessate possono accedere alla diretta e alla registrazione attraverso il sito web delle relazioni con gli investitori dell'azienda. La registrazione sarà disponibile per tre mesi dopo la chiamata.
Ultragenyx Pharmaceutical (NASDAQ: RARE), una compañía biofarmacéutica especializada en productos novedosos para enfermedades genéticas raras y ultraras, ha anunciado una conferencia telefónica programada para el 13 de febrero de 2025, a las 5:00 p.m. ET. La llamada discutirá los resultados financieros de la compañía y proporcionará una actualización corporativa tanto para el cuarto trimestre como para el año completo que finaliza el 31 de diciembre de 2024. Los inversionistas y partes interesadas pueden acceder a la transmisión en vivo y a la repetición a través del sitio web de relaciones con inversionistas de la compañía. La repetición estará disponible durante tres meses después de la llamada.
Ultragenyx Pharmaceutical (NASDAQ: RARE)는 희귀 및 극희귀 유전 질환을 위한 혁신적인 제품을 전문으로 하는 생명공학 회사로서 2025년 2월 13일 오후 5시 ET로 예정된 컨퍼런스 콜을 발표했습니다. 이 통화에서는 회사의 재무 결과를 논의하고 2024년 12월 31일로 마감되는 4분기 및 전체 연도의 기업 업데이트를 제공합니다. 투자자 및 관심 있는 당사자는 회사의 투자자 관계 웹사이트를 통해 실시간 웹캐스트 및 재생에 접근할 수 있습니다. 재생은 통화 후 3개월 동안 제공됩니다.
Ultragenyx Pharmaceutical (NASDAQ: RARE), une société biopharmaceutique spécialisée dans les produits novateurs pour les maladies génétiques rares et ultraraires, a annoncé une conférence téléphonique prévue pour le 13 février 2025 à 17h00 ET. L'appel portera sur les résultats financiers de l'entreprise et fournira une mise à jour sur les activités pour le quatrième trimestre et l'année entière se terminant le 31 décembre 2024. Les investisseurs et les parties intéressées peuvent accéder à la diffusion en direct et à la rediffusion via le site Web des relations avec les investisseurs de l'entreprise. La rediffusion sera disponible pendant trois mois suivant l'appel.
Ultragenyx Pharmaceutical (NASDAQ: RARE), ein biopharmazeutisches Unternehmen, das sich auf neuartige Produkte für seltene und ultrarare genetische Erkrankungen spezialisiert hat, hat eine Telefonkonferenz für den 13. Februar 2025 um 17:00 Uhr ET angekündigt. In der Konferenz werden die finanziellen Ergebnisse des Unternehmens besprochen und es gibt ein Unternehmensupdate für das vierte Quartal sowie das gesamte Jahr, das am 31. Dezember 2024 endet. Investoren und interessierte Parteien können über die Unternehmenswebsite für Investor Relations auf die Live-Übertragung und das Replay zugreifen. Das Replay wird drei Monate nach der Konferenz verfügbar sein.
- None.
- None.
NOVATO, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Thursday, February 13, 2025, to discuss its financial results and corporate update for the quarter and the year ending December 31, 2024.
The live and replayed webcast of the call will be available through the company’s website at https://ir.ultragenyx.com/events-presentations. The replay of the call will be available for three months.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contact Ultragenyx
Investors
Joshua Higa
(415) 475-6370
ir@ultragenyx.com
Media
Carolyn Wang
(415) 225-5050
media@ultragenyx.com
FAQ
When is Ultragenyx (RARE) reporting Q4 and full-year 2024 earnings?
How can investors access Ultragenyx's (RARE) Q4 2024 earnings call?
How long will the replay of Ultragenyx's (RARE) Q4 2024 earnings call be available?
What period will Ultragenyx's (RARE) upcoming earnings report cover?
